Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Perez, Edith A, Dr, Awada, Ahmad, MD, O'Shaughnessy, Joyce, MD, Rugo, Hope S, MD, Twelves, Chris, MD, Im, Seock-Ah, MD, Gómez-Pardo, Patricia, MD, Schwartzberg, Lee S, MD, Diéras, Veronique, MD, Yardley, Denise A, MD, Potter, David A, MD, Mailliez, Audrey, MD, Moreno-Aspitia, Alvaro, MD, Ahn, Jin-Seok, MD, Zhao, Carol, MS, Hoch, Ute, PhD, Tagliaferri, Mary, MD, Hannah, Alison L, MD, Cortes, Javier, MD
Published in The lancet oncology (01.11.2015)
Published in The lancet oncology (01.11.2015)
Get full text
Journal Article